Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis

European Journal of Cancer

Volumn 34, Issue 1, 1998, Pages 92-97

  Etienne, M C ^a   Chatelut, E ^b   Pivot, X ^a   Lavit, M ^b   Pujol, A ^b   Canal, P ^b   Milano, G ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

5 fluorouracil; NONMEM analysis; Pharmacokinetics

Indexed keywords

ALKALINE PHOSPHATASE; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ADULT; AGE; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; COMPUTER PROGRAM; CONTINUOUS INFUSION; DRUG CLEARANCE; DRUG INFUSION; ESOPHAGUS CANCER; FEMALE; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BODY SURFACE AREA; DIHYDROURACIL DEHYDROGENASE (NADP); ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; NEOPLASMS; OXIDOREDUCTASES; SEX FACTORS; TIME FACTORS;

EID: 0031890613     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00345-6     Document Type: Article

References (42)

1. Poon MA, O'Connel MJ, Moertel CG, et al. Biochemical modulation of fluorouracil with leucovorin. Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989, 7, 14071417.
2. Au JL, Sadee W. 5-fluorouracil concentrations in human plasma following R, S-l-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) administration. Cancer Res 1979, 42, 4289-4290.
3. Van Groeningen CJ, Pinedo HM, Heddes J, et al. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 1988,48,6956-6961.
4. Remick SC, Grem JL, Fischer PH, et al. Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion. Cancer Res 1990, SO, 2667-2672.
5. Trump DL, Egorin MJ, Forrest A, Willson JKV, Remick S, Tutsch KD. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol 1991, 9, 2027-2035.
6. Thyss A, Milano G, Renée N, Vallicioni J, Schneider M, Demard F. Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol 1986, 16, 64-66.
7. Milano G, Roman P, Khater R, Frenay M, Renée N, Namer M. Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU. IntJ Cancer 1988, 41, 537-541.
8. Hillcoat BL, McCulloch PB, Figueredo AT, Ehsan MH, Rosenfeld JM. Clinical response and plasma levels of 5-fluorouracil in patients with colonie cancer treated by drug infusion. Br J Cancer 1978, 38, 719-724.
9. Milano G, Etienne MC, Renée N, et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 1994, 12, 1291-1295.
10. Santini J, Milano G, Thyss A, et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 1989, 59, 287-290.
11. Coudert B, De Gislain C, Beltramo R, et al. Feasibility of 5-FU therapeutic monitoring. Eur} Cancer 1995, 31A (Suppl. 5), 201.
12. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinetics 1989, 16, 215-237.
13. Ho DH, Townsend L, Luma MA, Bodey GP. Distribution and inhibition of dihydrouracil dehydrogenase in human tissues using 5-fluorouracil as a substrate. Anticancer Res 1986, 6, 781-784.
14. Harris BE, Song R, Soong S, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990, SO, 197-201.
15. Fleming RA, Milano G, Thyss A, et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 1992, 52, 2899-2905.
16. Chazal M, Etienne MC, Renée N, Bourgeon A, Richelme H, Milano G. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin Cancer Res 1996, 2, 507-510.
17. Floyd RA, Hornbeck CL, Byfield JE. Clearance of continuously infused 5-fluorouracil in adults having lung or gastrointestinal carcinoma with or without hepatic métastases. Drug Intell Clin Pharm 1982, 16, 665-669.
18. Nowakowska-Dulawa E. Circadian rhythm of 5-fluorouracil pharmacokinetics and tolerance. Chronobiologia 1990, 17, 27-32.
19. Breimer DD. Variability in human drug metabolism and its implication. IntJ Clin Pharm Res 1983, 3, 399-13.
20. Milano G, Etienne MC, Cassuto-Viguier E, et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol 1992, 10, 1171-1175.
21. Sheiner LB, Grasela TH. Experience with NONMEM: analysis of routine phenytoin clinical pharmacokinetic data. Drug Metab Rev 1984, IS, 293-303.
22. Beal SL, Sheiner LB. Methodology of population pharmacokinetics. In Garrett ER, Hirtz J, eds. Drug Fate and Metabolism. New York, Marcel Decker, 1985, Vol. 5, 135-183.
23. Boekmann AJ, Sheiner LB, Beal SL. NONMEM User's Guide, Pan V: Introductory Guide. Technical Report of the Division of Clinical Pharmacology, University of California, San Francisco, University of California, 1992.
24. Beal SL, Boekmann AJ, Sheiner LB. NONMEM User's Guide, Pan VI: PREDPP Guide. Technical Report of the Division of Clinical Pharmacology, University of California. San Francisco: University of California, 1992.
25. Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Nat! Cancer Inst 1995, 87, 573-580.
26. Haaz MC, Fischel JL, Formento P, et al. Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase. Cancer Chemoiker Pharmacol 1996, 38, 52-58.
27. Etienne MC, Bernard S, Fischel JL, et al. Close reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head und neck carcinoma cell lines. Br J Cancer 1991, 63, 372-377.
28. Scanion KJ, Newman EM, Lu Y, et al. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc NatlAcadSti USA 1986, 8:, 8923-8925.
29. Shirasaka T, Shimamoto Y, Cheshimo H, et al. Metabolic basis of the synergistic antitumor activities of 5-1luorouracil and cisplatin in rodent tumor models in vivo. Career Chemother Pharmacol 1993, 32, 167-172.
30. Dumas C, Loi CM, Cusack BJ. Hepatic drug metabolism and aging. Clin Pharmacokinet 1990, 19, 359-389.
31. Lu Z, Zhang R, Diasio RB. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin Pharmacol Ther 1995, 58, 512-522.
32. Boublil JL, Milano G, Khater R, et al. Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation. Br J Cancer 1985, 52, 15-21.
33. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver. Population characteristics, newly identified deficient patients and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993, 53, 5433-5438.
34. Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994, 12, 2248-2253.
35. Yokes EE, Mick R, Kies MS, et al, Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol 1996, 14, 1663-1671.
36. Houyau P, Gay C, Chatelut E, et al. Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. J Nat! Cancer Inst 1993, 85, 1602-1603.
37. Milano G, Etienne MC. Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Pharmacogenetics 1994, 4, 301-306.
38. Stephan F, Etienne MC, Wallays C, et al. Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities. AmJMed 1995, 99, 685-688.
39. Fleming RA, Milano G, Etienne MC, et al No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion, rjCancer 1992,66, 668-672.
40. Fety R, Rolland F, Barbery-Heyob M, et al. Clinical randomized study of 5FU monitoring versus standard dose in patients with head and neck cancer: preliminary results. Anticancer Res 1994, 14, 2347.
41. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7, 1748-1756.
42. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996, 14, 2990-2998.